Evoke Pharma (EVOK) Stock Price, Quote & News

Company Profile

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was i...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 858 345 1494

Website: www.evokepharma.com

Address:

420 Stevens Avenue, Suite 230, Solana Beach, United States

d_risk Aug. 14 at 3:55 PM

$EVOK - Evoke Pharma Inc - 10Q - Updated Risk Factors EVOK warns new and pending healthcare laws could raise costs, complicate Gimoti commercialization, and pressure pricing and post-approval activities. #Pharmaceuticals #RegulatoryRisk #ProductCommercialization #PricingPressure #HealthcareRegulation 🟢 Added 🟠 Removed https://d-risk.ai/EVOK/10-Q/2025-08-14

0 · Reply

Rampageusa Aug. 8 at 2:56 PM

$EVOK lets go 12+

0 · Reply

BearTamerTrading Aug. 7 at 3:57 AM

We had a blast on this play and many others. We secured gains left and right this morning. Check out the screenshots for proof. I don’t really care to prove myself but I want to help as many traders as I can from the plays I call. See you guys at 6am to do it again ! I truly love the people in my community as they also add so much value ! And yes it’s free, just subscribe or don’t, it’s all good. https://youtube.com/@beartamertrading?si=rnXL5tqNEgU7MdOB $BTAI $SGBX $AIMD $KNW $EVOK

2 · Reply

Rampageusa Aug. 6 at 9:07 PM

$EVOK Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

0 · Reply

BearTamerTrading Aug. 6 at 8:47 PM

$AIMD $EVOK We caught both of these plays in PM, although $EVOK flopped soon after we secured those gains. See you guys tomorrow on the live trading stream 6 am sharp. https://youtube.com/@beartamertrading?si=br5hqd37KYzRFGzj

1 · Reply

Marcos211 Aug. 6 at 8:33 PM

Looks like volume and momentum are going to be shifting back in to CMCT now! Shorts overextended and now bulls can have them trapped at the bottom. CMCT Could make a huge multi day run - only 500k float for public! Don't miss CMCT ... it's breaking out now! $LKNCY $REBN $STAF $EVOK movers

1 · Reply

Rampageusa Aug. 6 at 4:04 PM

$EVOK only 15k more available to short..we will squeeze to 9.5/15

0 · Reply

itrekntravel Aug. 6 at 3:41 PM

$EVOK

0 · Reply

Rampageusa Aug. 6 at 2:55 PM

$EVOK show me 9.5/12

0 · Reply

jwdnl33 Aug. 6 at 2:28 PM

$EVOK let’s keeping climbing little guy!

0 · Reply

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Jul 9, 2025, 8:16 AM EDT - 5 weeks ago

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

May 13, 2025, 4:05 PM EDT - 3 months ago

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 8:30 AM EDT - 3 months ago

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Mar 13, 2025, 8:36 PM EDT - 5 months ago

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 5 months ago

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 8:30 AM EST - 5 months ago

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

Feb 24, 2025, 8:30 AM EST - 6 months ago

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Dec 19, 2024, 8:30 AM EST - 8 months ago

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

Dec 3, 2024, 8:30 AM EST - 9 months ago

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

Nov 14, 2024, 8:00 AM EST - 9 months ago

InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience

Nov 7, 2024, 4:05 PM EST - 10 months ago

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 12:34 PM EDT - 10 months ago

Evoke Pharma stock surges over 100%—here's why

Oct 23, 2024, 8:30 AM EDT - 10 months ago

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Oct 22, 2024, 8:30 AM EDT - 10 months ago

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Oct 1, 2024, 8:30 AM EDT - 11 months ago

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Sep 19, 2024, 2:20 PM EDT - 11 months ago

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Sep 18, 2024, 4:00 PM EDT - 11 months ago

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Sep 4, 2024, 9:20 AM EDT - 1 year ago

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Announces Reverse Stock Split

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

May 16, 2024, 4:02 PM EDT - 1 year ago

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

May 14, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Reports First Quarter 2024 Financial Results

Apr 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Mar 21, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Mar 14, 2024, 9:33 PM EDT - 1 year ago

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 4:10 PM EST - 1 year ago

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Feb 14, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Feb 9, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Jan 29, 2024, 9:00 AM EST - 1 year ago

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

Nov 27, 2023, 8:30 AM EST - 1 year ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

Nov 14, 2023, 8:30 AM EST - 1 year ago

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Nov 9, 2023, 8:30 AM EST - 1 year ago

Evoke Pharma Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 8:30 AM EDT - 1 year ago

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

Aug 10, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Jul 25, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Jun 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment

May 15, 2023, 4:05 PM EDT - 2 years ago

Evoke Pharma Reports First Quarter 2023 Financial Results

May 9, 2023, 7:00 AM EDT - 2 years ago

Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

May 4, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma's Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

May 1, 2023, 8:30 AM EDT - 2 years ago

New GIMOTI Patent Listed in FDA Orange Book

Apr 20, 2023, 8:30 AM EDT - 2 years ago

United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI

Apr 6, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent

d_risk Aug. 14 at 3:55 PM

0 · Reply

Rampageusa Aug. 8 at 2:56 PM

$EVOK lets go 12+

0 · Reply

BearTamerTrading Aug. 7 at 3:57 AM

2 · Reply

Rampageusa Aug. 6 at 9:07 PM

$EVOK Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

0 · Reply

BearTamerTrading Aug. 6 at 8:47 PM

1 · Reply

Marcos211 Aug. 6 at 8:33 PM

1 · Reply

Rampageusa Aug. 6 at 4:04 PM

$EVOK only 15k more available to short..we will squeeze to 9.5/15

0 · Reply

itrekntravel Aug. 6 at 3:41 PM

$EVOK

0 · Reply

Rampageusa Aug. 6 at 2:55 PM

$EVOK show me 9.5/12

0 · Reply

jwdnl33 Aug. 6 at 2:28 PM

$EVOK let’s keeping climbing little guy!

0 · Reply

iTradeHalfAsleep Aug. 6 at 12:06 PM

$EVOK 😶‍🌫️↗️

0 · Reply

YoloAlfred Aug. 6 at 11:48 AM

$EVOK 🤔🤔

0 · Reply

Thestocktraderhubzee Aug. 6 at 10:38 AM

WATCHLIST AUG 06 2025 $EVOK Evoke Pharma Secures New U.S. Patent For GIMOTI Nasal Spray Targeting Moderate To Severe Gastroparesis $ZBRA Needham Maintains Buy on Zebra Technologies, Raises Price Target to $345 $DIS Walt Disney Company Says ESPN Launches $29.99/Month Direct-To-Consumer Streaming Service And Enhanced App On August 21 Ahead Of College Football And NFL Seasons $ZETA Zeta Global shares are trading higher after the company raised its FY2025 sales guidance above estimates. $INTT InTest Corporation Secures $2.6M Defense Industry Order For Ultra-Low Temperature Thermal Test Systems

0 · Reply

Tradeforincome Aug. 5 at 6:38 PM

$EVOK huge wall at 5.60 headed back to 3 again!

0 · Reply

Stock_Catcher Aug. 5 at 1:52 AM

Money Tuesday Watchlist Pt. 4 $APPS $QNTM $BCRX $EVOK $BINI Let's Bounce Bulls ⚡📈

0 · Reply

StockScanners Aug. 5 at 1:26 AM

$EVOK reached 5.65 team

0 · Reply

Tradeforincome Aug. 5 at 12:57 AM

$EVOK 2 Green Day’s in a row. Q the buyout rumors!

0 · Reply

FloatRaider Aug. 4 at 7:57 PM

$EVOK volume surge! IBG is trading under $0.70 with multiple high-impact assets behind it: — FDA-certified facility — RNDC + Sysco U.S. distribution — Award-winning bitters brands Big institutional interest building quietly. #FundamentalsMeetMomentum

0 · Reply

FloatRaider Aug. 4 at 7:57 PM

$EVOK patenttttttt newsssss IBG is trading under $0.70 with multiple high-impact assets behind it: — FDA-certified facility — RNDC + Sysco U.S. distribution — Award-winning bitters brands Big institutional interest building quietly. #FundamentalsMeetMomentum

0 · Reply

PatentGrants Aug. 4 at 7:56 PM

$EVOK Evoke Pharma will be issued US patent number 12,377,064 tomorrow titled "TREATMENT OF MODERATE AND SEVERE GASTROPARESIS".

0 · Reply

itrekntravel Aug. 4 at 3:18 PM

$EVOK low volume, but what's driving sentiment here? is something expected in presentation?

0 · Reply

Rampageusa Aug. 4 at 2:57 PM

$EVOK push it back to 9.5

0 · Reply

Market Cap	7.36M
Revenue (ttm)	10.25M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.20%
Debt to Equity Ratio	0.00

Volume	28,500
Avg Vol	2,940,038
Day's Range	N/A - N/A
Shares Out	1.49M
Stochastic %K	45%
Beta	-0.04
Analysts	Hold
Price Target	$10.00